Posted by Michael Wonder on 31 Mar 2021
Evive Biotech submits biologics license application to US FDA for Ryzneuta
31 March 2021 - Evive is the first Chinese biologics company to advance a novel biologic product from pre-clinical studies to a completed BLA submission.
Evive Biotech, a global biologics company developing novel biologic therapies, today announced the submission of its biologics license application for Ryzneuta (also known as F-627) to the US FDA.
The submission follows the successful conclusion of Evive’s Global Phase 3 clinical trials, which met its primary and secondary outcomes, demonstrating strong and lasting benefit for patients.
